Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Grows By 28.2%

Aquestive Therapeutics, Inc. (NASDAQ:AQSTGet Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 2,320,000 shares, a growth of 28.2% from the February 29th total of 1,810,000 shares. Based on an average daily volume of 1,870,000 shares, the short-interest ratio is currently 1.2 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AQST shares. Raymond James started coverage on Aquestive Therapeutics in a report on Thursday. They issued an “outperform” rating and a $7.00 target price for the company. JMP Securities upped their price objective on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Friday, March 15th. Finally, HC Wainwright lifted their target price on shares of Aquestive Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Monday, March 18th.

View Our Latest Stock Analysis on AQST

Aquestive Therapeutics Trading Up 3.9 %

AQST opened at $4.26 on Monday. The business has a 50 day moving average of $3.56 and a 200-day moving average of $2.46. The stock has a market capitalization of $312.26 million, a price-to-earnings ratio of -30.43 and a beta of 2.85. Aquestive Therapeutics has a 1-year low of $0.90 and a 1-year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQSTGet Free Report) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The business had revenue of $13.21 million for the quarter, compared to the consensus estimate of $11.79 million. Equities analysts predict that Aquestive Therapeutics will post -0.38 EPS for the current year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 50,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the sale, the insider now directly owns 984,476 shares in the company, valued at $5,906,856. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.39% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Large investors have recently added to or reduced their stakes in the company. Northern Trust Corp increased its stake in Aquestive Therapeutics by 9.5% in the second quarter. Northern Trust Corp now owns 65,500 shares of the company’s stock valued at $108,000 after acquiring an additional 5,672 shares during the period. State Street Corp lifted its position in shares of Aquestive Therapeutics by 10.3% during the 1st quarter. State Street Corp now owns 96,037 shares of the company’s stock worth $251,000 after buying an additional 8,960 shares during the period. PDT Partners LLC boosted its stake in Aquestive Therapeutics by 10.7% in the 1st quarter. PDT Partners LLC now owns 101,456 shares of the company’s stock valued at $265,000 after buying an additional 9,845 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Aquestive Therapeutics during the second quarter worth $28,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of Aquestive Therapeutics by 118.2% during the first quarter. BNP Paribas Arbitrage SA now owns 34,810 shares of the company’s stock valued at $91,000 after acquiring an additional 18,860 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Recommended Stories

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with's FREE daily email newsletter.